A recent study reported that about 26% of Ethiopian breast cancer patients had germline CYP2D6 amplifications, predicting a significantly increased plasma concentration of endoxifen, the active tamoxifen metabolite, in most cases [92]. Here, CYP2D6 is linked to breast cancer.